PALOMID 529

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H22O6
Molecular Weight	406.4279
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(COC2=CC3=C(C=C2OC)C4=C(C=C(C=C4)C(C)O)C(=O)O3)C=C1

InChI

InChIKey=YEAHTLOYHVWAKW-UHFFFAOYSA-N

InChI=1S/C24H22O6/c1-14(25)16-6-9-18-19-11-22(28-3)23(12-21(19)30-24(26)20(18)10-16)29-13-15-4-7-17(27-2)8-5-15/h4-12,14,25H,13H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C24H22O6
Molecular Weight	406.4279
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19010932 | https://www.ncbi.nlm.nih.gov/pubmed/26918392

RES-529 (previously named Palomid 529, P529) is a phosphoinositide 3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) pathway inhibitor that interferes with the pathway through both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) dissociation. P529 inhibits tumor growth, angiogenesis, and vascular permeability. It retains the beneficial aspects of tumor vascular normalization that rapamycin boasts. This compound is currently being developed in oncology and ophthalmology. The oncology focus is for the treatment of glioblastoma, where it has received orphan designation by the US Food and Drug Administration, and prostate cancer.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mammalian target of Rapamycin (mTORC1) 23 Target ID: CHEMBL2221341 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19010932 \| https://www.ncbi.nlm.nih.gov/pubmed/26918392	Inhibitor 8297
TORC2 complex 3 Target ID: GO:0031932 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19010932 \| https://www.ncbi.nlm.nih.gov/pubmed/26918392	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Age-related macular degeneration 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23689994 http://adisinsight.springer.com/drugs/800028147	Primary	Phase I 428	Unknown Approved Use Unknown
Prostate cancer 178 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19240717 https://www.ncbi.nlm.nih.gov/pubmed/21551258 https://www.ncbi.nlm.nih.gov/pubmed/24715588	Primary	Preclinical	Unknown Approved Use Unknown
Glioblastoma 65 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23436212 http://globenewswire.com/news-release/2015/01/28/700603/10117109/en/RestorGenex-Granted-Orphan-Drug-Designation-for-RES-529-for-Treatment-of-Glioblastoma-Multiforme.html	Primary	Preclinical	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY579622	https://www.001chemical.com/chem/914913-88-5
AA Blocks	AA00GU2H	https://www.aablocks.com/goods/Goods/detail?id=AA00GU2H
AEchem Scientific Corp., USA	AE027724	http://www.aechemsc.com/info_products/AE027724.php
AK Scientific, Inc. (AKSCI)	SYN5215	http://www.aksci.com/item_detail.php?cat=SYN5215
AK Scientific, Inc. (AKSCI)	Y0291	http://www.aksci.com/item_detail.php?cat=Y0291
Aaron Chemicals	AR00GUU9	http://www.aaronchem.com/914913-88-5
AbMole Bioscience	1760	http://www.abmole.com/product.asp?id=1760
AbMole Bioscience	M1760	http://www.abmole.com/products/palomid-529.html
Achemtek	0102-013226	http://www.achemtek.com/914913-88-5
Acorn PharmaTech	ACN-030389	http://www.acornpharmatech.com/
Active Biopharma	ABP000907	http://www.activebiopharma.com/914913-88-5
Adooq BioScience	Palomid 529 - P529	http://www.adooq.com/palomid-529-p529.html
Alsachim	4538	http://www.alsachim.com/product-C5881-glo.bal-view.html
Ambinter	Amb22169297	http://www.ambinter.com/reference/22169297
Angel Pharmatech	AG-12038	http://www.angelpharmatech.com/914913-88-5.html
Angene	AGN-PC-00JIQP	http://www.angenechemical.com/productshow/AGN-PC-00JIQP.html
Ark Pharm	AK160239	http://www.arkpharminc.com/products/914913-88-5.html
Ark Pharma Scientific Limited	A-0311	http://www.arkpharmtech.com/product/32262.html
Aurora Fine Chemicals LLC	A24.092.576	http://online.aurorafinechemicals.com/info?ID=A24.092.576
Aurora Fine Chemicals LLC	K16.647.336	http://online.aurorafinechemicals.com/info?ID=K16.647.336
Aurum Pharmatech LLC	W-5766	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5766
Axon MedChem	1718	https://www.axonmedchem.com/product/1718
BOC Sciences	914913-88-5	https://www.bocsci.com/palomid-529-cas-914913-88-5-item-84-307761.html
BioChemPartner	BCP02474	http://www.biochempartner.com/914913-88-5-BCP02474
BioCrick	BCC3905	http://www.biocrick.com/Palomid-529-BCC3905.html
BioSynth	J-519339	https://www.biosynth.com/en/products/all-products/products/J-519339.html
Boerchem	BC638799	http://www.boerchem.com/?product_42960.html
Chem Scene	CS-0258	http://www.chemscene.com/914913-88-5.html
ChemShuttle	140535	http://www.chemshuttle.com/catalogsearch/result/?q=914913-88-5&cat=
Chemspace	CSSB00016992627	https://chem-space.com/CSSB00016992627
Combi-Blocks	QJ-9714	http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-9714
DC Chemicals	DC7223	http://www.dcchemicals.com/product_show-Palomid_529_P529_.html
Excenen	EX-A254	http://www.excenen.com/searchresultlist.php?id=914913-88-5
Lab Network	LN01289900	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01289900
MedChem Express	HY-14581	https://www.medchemexpress.com/Palomid-529.html
MolPort	MolPort-023-293-524	https://www.molport.com/shop/molecule-link/MolPort-023-293-524
Molcore	MC579622	https://www.molcore.com/product/914913-88-5
MuseChem	I005454	https://www.musechem.com/product/I005454.html
Renno Tech	RL05762	http://www.rennotech.com/product_show.asp?id=6010
Selleck Chemicals	S2238	http://www.selleckchem.com/products/Palomid-529-P529.html
Smolecule	S548184	http://www.smolecule.com/products/s548184
Synblock Inc	SB16564	http://www.synblock.com/product/914913-88-5.html
THE BioTek	bt-287593	https://www.thebiotek.com/product/inhibitors/bt-287593
VladaChem	VL265545-10MG	https://www.vladachem.com/product.php?products=914913-88-5
abcr GmbH	AB479759	http://www.abcr.com/shop/en/AB479759
eNovation Chemicals	D297321	https://www.enovationchem.com/ProductDetails.asp?ProductID=D297321
eNovation Chemicals	Y0974054	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974054

PubMed

Title	Date	PubMed
		252160392
The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer.	2009 Mar 24	19240717

Patents

Sample Use Guides

In Vivo Use Guide

Five participants with neovascular age-related macular degeneration that were refractory to intravitreal anti-vascular endothelial growth factor (VEGF) received three serial monthly subconjunctival doses of 1.9 mg Palomid 529. Mice were treated s.c. with 20 mg/kg Palomid 529 every 3 days.

Route of Administration: Other

In Vitro Use Guide

Palomid 529 showed a potent antiproliferative activity in the NCI-60 cell lines panel, with growth inhibitory 50 (GI50) <35 microM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:59:24 GMT 2023` Edited by `admin` on `Fri Dec 15 17:59:24 GMT 2023`
Record UNII	XV9409EWG4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PALOMID 529

Common Name

English

SG 00529

Code

English

6H-DIBENZO(B,D)PYRAN-6-ONE, 8-(1-HYDROXYETHYL)-2-METHOXY-3-((4-METHOXYPHENYL)METHOXY)-

Systematic Name

English

8-(1-HYDROXY-ETHYL)-2-METHOXY-3-(4-METHOXY-BENZYLOXY)-BENZO(C)CHROMEN-6-ONE

Systematic Name

English

PALOMID-529

Code

English

P-529

Code

English

P529

Code

English

SG-00529

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

463714